What Are Chinese Pharma CEOs Ranting About? (Part 2 of 2)
Top pharma executives get the chance to air their grievances during a once-a-year “meet the regulators” session in Beijing. In this second part of coverage of the meeting, China FDA director Wang Lifeng discusses marketing authorization holder pilots while CEOs including Betta’s Ding Lieming touch upon provincial tenders, orphan drugs and patent invalidity appeals.